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Introduction
Osteosarcoma (OS) is the most common malignant bone cancer, with a high incidence of lung metastasis and a poor prognosis (1, 2) . With advances in treatment strategies, the mean 5-year survival rate of OS patients has increased considerably from 20 to 70% with current neoadjuvant chemotherapy combined with primary tumour resection (3, 4) . However, over 30% of OS patients experience metastasis, leading to a poor prognosis (5) . A better understanding of the complexity of OS is essential to improve the treatment of this devastating disease. Investigations into the molecular mechanisms underlying the initiation and progression of OS are warranted to identify and develop reliable diagnostic and prognostic markers.
Centrosomal protein 55 (CEP55) is a microtubule-bundling protein located at the mitotic spindle during prometaphase and metaphase that was initially identified as a key regulator of cytokinesis (6) . Subsequent studies showed that CEP55 might cooperate with members of the endosomal sorting complex required for transport machinery to constrict the intracellular bridge and allow abscission (7) . Recently, additional roles of CEP55 in regulating the PI3K/AKT pathway and promoting tumourigenesis have been reported (8, 9) . Accumulating evidence has shown that CEP55 is involved in the development and progression of various types of cancer, including prostate cancer, lung cancer, breast carcinoma and gastric cancer (9) (10) (11) (12) . In addition, CEP55 has been shown to regulate critical cell functions, including cell cycle and apoptosis (13) . Overexpression of CEP55 was found to enhance cell cycle transition, while knockdown of CEP55 inhibited breast and gastric cancer cell growth (11, 12, 14) . Inoda et al. (15) reported that Cep55/c10orf3 peptides are naturally expressed by breast cancer cells and can cause clonal expansion of cytotoxic T lymphocytes in vivo. In addition, Cep55/c10orf3_193 (10) peptides may be applied in therapeutic strategies for patients with hormone therapy-resistant breast carcinoma (15) .
Although CEP55 has been implicated as a prognostic gene for cancer, there is a paucity of studies specifically evaluating the expression and significance of CEP55 in OS. In this study, we investigated for the first time the clinical significance and biological activity of CEP55 in OS. We found that CEP55 expression level in OS correlated with metastasis and poor prognosis. Through in vivo and in vitro experiments, we further confirmed that CEP55 regulated the proliferation and invasion of OS cells, possibly through activation of CCND1 and FN1 via the AKT signalling pathway. These findings may shed light on the role of CEP55 in the initiation and progression of OS.
Methods

Patients and tissue samples
This study was approved by the ethics committee of the Affiliated Drum Tower Hospital of Nanjing University Medical School. Osteosarcoma specimens and corresponding adjacent normal tissues were obtained from 98 patients who underwent surgical interventions from June 2006 to May 2013. For immunohistochemistry analysis, all the samples were fixed in 10% formalin, embedded in paraffin and sectioned consecutively at 4 µm thickness. For expression analysis, a total of 21 tissue samples were immediately frozen and stored in liquid nitrogen until RNA or protein extraction. Baseline characteristics of the patients, including age, gender, Enneking stage, metastasis, tumour location, tumour recurrence and histologic subtype, were collected from medical records. All the patients received no chemotherapy prior to surgical resection. After surgery, patients underwent four cycles of chemotherapy consisting of cisplatin (100 mg/m 2 ), doxorubicin (80 mg/m 2 ) and high-dose methotrexate (10 g/ m 2 ). The patients were regularly followed up after treatment completion to determine the overall survival time. All patients signed the informed consent form.
Immunohistochemical staining
Paraffin-embedded tissue specimens were cut into 4 µm sections and deparaffinized. After performing antigen retrieval by microwave heating and blocking endogenous peroxidase, slides were incubated with primary anti-CEP55 antibody (1:400, Abcam Inc., Cambridge, MA) overnight at 4°C and then with secondary antibody for 30 min at room temperature. Finally, all slides were stained with diaminobenzidine and then counterstained with haematoxylin. Two pathologists who were blinded to the clinical information independently scored the immunohistochemistry-stained tissue sections. For the CEP55 staining assessment, the entire tissue section was scanned to calculate the score. The staining distribution was scored based on the percentage of positive cells as follows: score 0, 0%; score 1, 1-30%; score 2, 31-60%; and score 3, 61-100% (16) . The signal intensity was scored as follows: score 0, no signal; score 1, weak; score 2, moderate; and score 3, strong (16) . The final score was equal to the staining distribution score multiplied by the signal intensity score. Weak staining was defined as a score less than or equal to 3 (16) .
Immunofluorescence microscopy
Osteosarcoma samples from three cases were blocked in 1% bovine serum albumin in phosphate buffer solution (PBS) for 1 h at room temperature and then incubated with an antibody cocktail containing anti-CEP55 (monoclonal rabbit, Abcam Inc., Cambridge, MA) in blocking solution at 4°C overnight under humidified conditions. The sections were washed with PBS and then incubated with Alexa Fluor 555-conjugated secondary antibodies (Abcam Inc., Cambridge, MA) for 1 h at room temperature in the dark. The slides were protected from light during the following procedures. Slides were washed with PBS and stained with 4′,6′-diamidino-2-phenylindole (DAPI; Thermo Scientific Fremont, CA) for 5 min to identify nuclei. Then, they were washed with PBS and mounted in fluorescent quenching agent. Images were captured using a Zeiss Axio Lab.A1 fluorescence microscope (Carl Zeiss, Jena, Germany).
Cell culture and lentivirus transfection
The MNNG/HOS and U2OS human OS cell lines were purchased from the American Type Culture Collection (ATCC, Manassas, VA) in May 2016 and cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin at 37°C with 5% CO 2 .
Both cell lines were cytogenetically tested and authenticated before they were frozen. Lentivirus expressing shRNA targeting CEP55 (shCEP55) or negative control scramble shRNA (shCtrl) was designed and constructed by Shanghai Genechem Company Ltd., China. Lentivirus particles were generated by co-transfection of the recombinant vectors and packaging vectors into 293T cells using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). MNNG/HOS and U2OS cells were then cultured in six-well plates and transfected with shCEP55 or shCtrl. The transfected cells were cultured for another 5 days. The target gene knockdown efficiency was evaluated in both cell lines by quantitative real-time PCR (qRT-PCR) and western blot (WB) analysis.
Cell viability and proliferation assays
To determine the effect of CEP55 on cell viability, transfected cells were plated in 96-well plates at a density of 2 × 10 3 cells per well and cultured for 5 days after transfection. Every 24 h, MTT (20 μl of a 5 mg/ml solution; Genview) was added to each well, and the plates were incubated for 4 h. After the incubation, the medium was discarded, and 150 μl of dimethylsulfoxide was added to solubilize the formazan crystals. The absorbance was measured at 490 nm on a microplate reader.
For the cell proliferation analysis, cells were plated in 96-well plates at a density of 2 × 10 3 cells per well at 72 h after transfection. GFP-positive 
Cell cycle assay
Cells were harvested in the exponential growth phase, and single-cell suspensions containing 1 × 10 6 cells were fixed with pre-chilled 70% alcohol. Cell cycle was monitored using propidium iodide staining and measured with a Guava easyCyte HT flow cytometer (Millipore, Billerica, MA), and the results were analysed with ModFit 3.0 software (Verity Software House, Topsham, ME).
Apoptosis assay
Cell apoptosis was assayed by staining cells with Annexin V-APC (eBioscience, San Diego, CA) following the manufacturer's instructions and detected by the Guava easyCyte HT flow cytometer (Millipore, Billerica, MA, USA). Caspase-3/7 activity was measured using a Promega Caspase-Glo® 
Cell migration and invasion assays
Cell migration and invasion assays were performed using Transwell chambers with an 8-μm pore size (Corning, Corning, NY, USA) in a 24-well plate. For the migration assay, 5 × 10 4 cells in serum-free medium were placed in the upper chamber of the insert. For the invasion assay, 1 × 10 5 cells in serum-free medium were seeded in the upper chamber of Matrigelcoated inserts. Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (800 μl) was used as the chemoattractant in the lower chamber. After the indicated time, the medium was removed, and the cells remaining on the upper surface of the membrane were removed. Cells that had moved to the lower side of the membrane were stained with Giemsa (SigmaDiagnostics, St, Louis) and then imaged using an IX71 inverted microscope (Olympus, Tokyo, Japan).
In vivo OS tumour growth
Six-week-old male BALB/c nude mice were purchased from the Shanghai Institute of Biological Sciences (Shanghai, China). MNNG/HOS cells (5 × 10 6 ) transfected with shCEP55 or shCtrl were subcutaneously injected into two groups of nude mice after inducing anaesthesia by inhalation of a 1:1 mixture of isoflurane gas and oxygen. Beginning in the third week after inoculation, tumour size was evaluated twice per week based on the following formula: V (volume) = π × L (length) × W (width) 2 /6. At 4 weeks after inoculation, all mice were killed, and tumours were harvested and weighed. Animals were treated humanely, and all procedures were conducted in compliance with our institution's guidelines for the use of laboratory animals and approved by the Institutional Animal Care and Use Committee of our hospital.
Microarray processing and analysis
Total RNA from MNNG/HOS cells infected with lentivirus expressing shCEP55 (n = 3) or shCtrl (n = 3) was extracted using TRIzol. Then, RNA quantity and quality were assessed with a Thermo Nanodrop 2000 (Thermo Scientific, Wilmington, DE) and an Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). Affymetrix PrimeView Human Gene Expression Arrays (Thermo Scientific, Willmington, DE) were used for microarray analysis to obtain gene expression profiles according to the manufacturer's instructions. Significant differentially expressed genes were selected based on the following criteria: P < 0.05 and absolute fold change > 1.5. Pathway enrichment analysis was performed for all significant differentially expressed genes using the KEGG and BIOCARTA pathway databases. Significantly differentially expressed genes were selected for further validation in transfected cell lines and tissue samples from patients through qRT-PCR and WB.
RNA extraction and qRT-PCR analysis
Total RNA was extracted from cell lines, tumour tissues and corresponding adjacent normal tissues with TRIzol reagent (Invitrogen) as mentioned above. Gene expression levels were quantitated using SYBR Master Mix (TAKARA, Tokyo, Japan) on a LightCycler 480 (Roche Applied Science, Mannheim, Germany) with glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as the internal control. The amplification protocol included an initial denaturation step at 95°C for 10 min, followed by 40 cycles of denaturation at 95°C for 10 s, annealing at 60°C for 20 s and elongation at 72°C for 10 s. At the end of the cycling protocol, melting curve analyses were performed. Relative mRNA expression was analysed based on the 2 −∆∆Ct method.
Protein isolation and WB analysis
Cells were lysed on ice in RIPA buffer (1× phosphate-buffered saline, 1% NP40, 0.1% SDS, 5 mM ethylenediaminetetraacetic acid, 0.5% sodium deoxycholate and 1 mM sodium orthovanadate) supplemented with protease inhibitor cocktail (Complete ethylenediaminetetraacetic acid-free; Roche). For immunoblotting, equal amounts of cell lysates were separated on a 10-12% SDS polyacrylamide gel, electro-transferred to polyvinylidene fluoride membranes (Immobile P; Millipore) and blocked in 5% non-fat milk. Membranes were incubated with primary antibodies listed in the Supplementary Table 2 , available at Carcinogenesis Online, overnight at 4°C and then with corresponding secondary antibodies conjugated to horseradish peroxidase for 2 h at room temperature. The signals were detected by enhanced chemiluminescence. GAPDH was used as a loading control.
Statistical analysis
All statistical analyses were conducted using the SPSS statistical software package, version 13.0 (Abbott Laboratories, North Chicago, IL). The data are presented as the mean ± SD for continuous variables. The relationship between CEP55 expression and clinicopathological patient characteristics was analysed using Student's t-test and the chi-square test. Cumulative survival time was calculated by the Kaplan-Meier method and analysed by the log-rank test. Statistical significance was set at P < 0.05.
Results
CEP55 is overexpressed in OS tissues
Immunohistochemistry was performed on 98 pairs of tumour specimens and adjacent normal tissues to evaluate CEP55 expression. The baseline characteristics of the patients are summarized in Table 1 . In total, 85.7% (84/98) of adjacent normal tissues showed weak CEP55 staining. By contrast, strong positive CEP55 immunoreactivity was found in 59.2% (58/98) of tumour tissues (Figure 1a) . To validate the results of the immunohistochemical analysis, we assessed CEP55 expression in 21 pairs of OS specimens by qRT-PCR and WB. CEP55 was significantly overexpressed in tumour tissues compared with normal tissues (Figure 1b and c) . Immunofluorescence results showed that CEP55 was primarily located at the plasma membrane of OS cells (Supplementary Figure 1 , available at Carcinogenesis Online).
Overexpression of CEP55 is associated with OS progression and clinical outcome
To investigate whether CEP55 expression can be used as a prognostic indicator of the clinical outcome of patients with OS, we classified the patients into the weak expression group and the strong expression group according to the immunohistochemical results. As shown in Table 1 , CEP55 expression was significantly associated with tumour size (P = 0.03) and tumour metastasis (P = 0.04). The 5-year survival rate was 77.5% (31/40) for patients with low CEP55 expression and 55.2% (32/58) for patients with high CEP55 expression (P = 0.04). Kaplan-Meier analysis further revealed that high CEP55 expression levels were obviously associated with reduced overall survival of OS patients (Figure 1d ). There was no significant association between CEP55 expression and other clinical pathological features, including age at surgery, gender, Enneking stage and the presence of local recurrence ( Table 1) .
Knockdown of CEP55 inhibits OS cell proliferation in vivo and in vitro
To further investigate the biological role of CEP55 in OS, we developed stable clones of MNNG/HOS and U2OS cells transfected with lentivirus expressing shCEP55 or shCtrl (Figure 2a and Supplementary Figure 2a , available at Carcinogenesis Online). A knockdown efficiency of more than 70% was confirmed by qRT-PCR and WB (Figure 2b and Supplementary Figure 2b , available at Carcinogenesis Online). Cells with CEP55 knockdown had a significantly decreased proliferation rate compared with those transfected with control vector (P < 0.001) (Figure 2c and Supplementary Figure 2c , available at Carcinogenesis Online). In addition, CEP55-knockdown cells generated obviously smaller xenografts in nude mice than control cells (Figure 2d ).
Knockdown of CEP55 induces cell cycle arrest and promotes apoptosis
To elucidate the mechanism by which CEP55 contributes to OS cell proliferation, cell cycle changes were analysed through FACS analysis. After silencing CEP55 expression, we observed a marked increase in cells in G1 phase and a decline in cells entering S and G2/M phases (Figure 3a) . Moreover, annexin V staining showed an increased apoptosis rate, and the apoptosis indicator cleaved caspase-3/7 was detected after knockdown of CEP55 (Figure 3b ).
Knockdown of CEP55 inhibits OS cell migration and invasion in vitro
Inspired by the results of the Kaplan-Meier analyses, we speculated that CEP55 overexpression may play a role in the metastatic activity of tumour cells. Consequently, we compared the migration and invasion abilities of OS cell lines transfected with shCtrl or shCEP55. For the MNNG/HOS cell lines, the migration and invasion rates of control cells were 2.1-fold and 2.4-fold higher, respectively, than those of transfected cells (P < 0.001) (Figure 4a ). For the U2OS cell lines, the migration and invasion rates of control cells were 2.2-fold and 2.5-fold higher, respectively, than those of transfected cells (P < 0.001) (Figure 4b ). 
CEP55 may mediate OS development via the AKT signalling pathway
Global gene expression profiles of MNNG/HOS cells infected with lentivirus expressing either shCtrl or shCEP55 were obtained to discover the mechanism underlying the CEP55-mediated development of OS. In total, 677 significant differentially expressed genes were identified, including 237 up-regulated genes and 340 down-regulated genes (Figure 5a ). KEGG pathway analysis and functional interaction network analysis showed that several differentially expressed genes were enriched in the AKT pathway, which is the most frequently reported pathway to be associated with OS (Figure 5b ). Subsequently, we used WB to validate the differential protein expression of six genes in the AKT pathway in transfected cells (Figure 5c ). Then, the expression of these six genes was further detected in 21 pairs of tumour tissues and adjacent normal tissues. CCND1 and FN1 were significantly upregulated in tumour tissues, and their mRNA expression levels were strongly correlated with CEP55 expression (r = 0.447, P = 0.03 for CCND1; r = 0.431, P = 0.04 for FN1) (Figure 5d ).
Discussion
Previous studies have identified CEP55 as a central regulator of tumour progression in several types of cancer. Although it is barely detectable in normal tissues, CEP55 is overexpressed in cancer tissues (17) (18) (19) . In this study, correlations between CEP55 expression and clinicopathologic variables were analysed in 98 OS patients. For the first time, we demonstrated that CEP55 is overexpressed in OS specimens, and the expression level is significantly associated with tumour size and the incidence of metastasis. Moreover, high CEP55 expression is strongly associated with decreased survival of patients with OS. Together, these data indicate that elevated CEP55 expression could play a role in the development and progression of OS. It has been well documented that high proliferative activity can increase the risk of tumour progression (20, 21) . In vitro analyses revealed that knockdown of CEP55 significantly decreased the proliferation of OS cell lines. This finding agreed with the result of the in vivo experiment, in which CEP55-knockdown cells generated smaller xenograft tumours in nude mice than control cells. Considering that resistance to cell death has been implicated in tumour proliferation (22, 23) , we further investigated the role of CEP55 in regulating the cell cycle of OS cell lines. Knockdown of CEP55 in OS cells increased the population of cells in G1 phase, with a corresponding decline in the population of cells entering S and G2/M phases. As one of the main cell cycle checkpoints, the G1/S transition plays a key role in the initiation and completion of DNA replication (24) . Previous studies have shown that CEP55 can modulate the cell cycle and apoptosis in multiple cancer cell lines (11, 13, 19) . Tao et al. reported that cell proliferation was suppressed due to cell cycle arrest in CEP55-knockdown gastric carcinoma cells (11) . Recently, it was reported that silencing CEP55 could promote the apoptosis of breast cancer cells (14) . Consistent with this report, we found that knockdown of CEP55 significantly increased the number of apoptotic OS cells. In addition, the apoptosis indicator cleaved caspase-3 was clearly detected in our study, suggesting that silencing CEP55 may induce OS cell apoptosis via cell cycle arrest.
We further investigated the potential regulatory pathway through which CEP55 modulates the proliferation and cell cycle progression of OS cells. Through analysis of the gene expression profiles of MNNG/HOS cells infected with shCEP55, we found that CEP55 knockdown may result in the inhibition of CCND1 via the AKT pathway. Consistently, there was a high correlation between CEP55 and CCND1 expression levels in OS patient specimens. Previous studies have shown that the AKT pathway is involved in regulating cell proliferation and apoptosis to affect the progression of OS (25, 26) . Moreover, as a cell cycle factor downstream of AKT signalling, CCND1 has been reported to play an important role in the development and progression of many different carcinomas (27) (28) (29) . Our findings suggest that AKT signalling may be responsible for CEP55-mediated OS cell proliferation. The mechanism connecting CEP55 and the AKT pathway is worthy of further exploration.
Previous studies have shown that CEP55 can regulate tumour cell migration, invasion and metastasis in various types of cancer (9, 18, 19) . In this study, we found that OS cell migration and invasion were dramatically suppressed after CEP55 knockdown. Interestingly, decreased FN1 expression was observed in OS cells transfected with shCEP55. Through qPCR and WB, we confirmed that FN1 was overexpressed in patients with OS, and its expression level was significantly correlated with that of CEP55. FN1 regulates cell migration and metastasis and is up-regulated in multiple types of cancer cells (30, 31) . High FN1 expression was reported to indicate the activation of epithelial-mesenchymal transition (EMT) in cancer tissues (31, 32) . There is accumulating evidence that EMT may play a critical role in tumour metastasis (33, 34) . Moreover, AKT signalling has also been recently identified as a key regulator of EMT induction (35) . Herein, we speculate that CEP55 may facilitate OS cell migration and invasion via activation of EMT, but the underlying mechanism requires further investigation.
Conclusions
Our study provides the first evidence that CEP55 overexpression in OS is correlated with tumour progression and clinical outcome. In addition, we identified CEP55 as a key regulator of OS cell proliferation, apoptosis and invasion, possibly via the regulation of FN1 and CCND1 through the AKT pathway. Our data suggest that CEP55 can be used as a prognostic marker for OS, highlighting the significance of CEP55 signalling as a putative therapeutic target.
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